Interestingly, we found that inhibition of EGFR by Gefitinib or Erlotinib led to inactivation of PI3K/Akt/mTOR and ERK pathways, but up-regulated IKK/NF-κB signalling in multiple HNSCC cells (Fig. 7, middle panel). This evidence concerns the gene NFKB1 and head and neck squamous cell carcinoma.